Propranolol Hydrochloride + AlprazolamThird Party Manufacturing in India

Propranolol Hydrochloride plus Alprazolam is a fixed-dose combination that targets both the sympathetic nervous system and the GABAergic inhibitory pathway. Propranolol acts as a non-selective beta-adrenergic receptor antagonist, competitively blocking the action of catecholamines at beta-1 and beta-2 receptors. By inhibiting beta-1 receptors in the myocardium, propranolol reduces heart rate, myocardial contractility, and cardiac output, thereby attenuating the peripheral physical symptoms of anxiety such as palpitations, tachycardia, and tremors. Beta-2 receptor blockade in bronchial and vascular smooth muscle contributes to its haemodynamic effects. Propranolol is highly lipophilic and readily crosses the blood-brain barrier, where it modulates central adrenergic signalling in the amygdala and prefrontal cortex, reducing the cognitive and emotional components of anxiety. Alprazolam, a triazolobenzodiazepine, binds to the benzodiazepine site on the gamma-aminobutyric acid (GABA)-A receptor complex. This binding potentiates GABA-mediated chloride ion influx, leading to neuronal hyperpolarisation and reduced excitability. The rapid onset of alprazolam provides immediate anxiolytic and sedative effects, while propranolol offers sustained control of somatic anxiety symptoms without the risk of dependence associated with benzodiazepine monotherapy. This complementary dual mechanism makes the combination particularly effective for anxiety disorders where both psychological and physical symptoms are prominent.

Therapeutic Uses

Propranolol Hydrochloride + Alprazolam combination is prescribed for:

• Generalised Anxiety Disorder (GAD): The combination effectively manages both the psychological worry component through alprazolam's GABAergic action and the physical somatic symptoms through propranolol's beta-blockade. It is especially useful in patients who present with prominent autonomic symptoms such as palpitations, sweating, and tremors.

• Panic Disorder with Palpitations: In patients experiencing panic attacks accompanied by prominent cardiovascular symptoms, propranolol attenuates tachycardia and chest discomfort while alprazolam reduces the acute anxiety episode.

• Performance Anxiety: The combination is used for situational anxiety where both anticipatory worry and physical manifestations such as tremor and heart palpitations impair performance.

• Essential Tremor with Anxiety: Propranolol is a first-line treatment for essential tremor, and the addition of alprazolam provides adjunctive anxiolytic benefit in patients whose tremor is exacerbated by anxiety.

• Social Anxiety Disorder: The beta-blocker component reduces blushing, sweating, and tachycardia while the benzodiazepine component alleviates the anticipatory fear of social situations.

Why Manufacturers Choose Propranolol Hydrochloride + Alprazolam

The Propranolol + Alprazolam combination is a high-demand psychiatric-cardiac formulation for Indian PCD franchise operators. It addresses the large patient population presenting with anxiety accompanied by physical cardiovascular symptoms. The combination formulation as a single tablet significantly improves patient compliance compared to separate medications. Indian manufacturers with WHO-GMP certification consistently report steady demand from domestic franchise networks and export markets across Asia and Africa. The manufacturing process is well-established with readily available APIs from domestic sources, and the tablet formulation allows for standard blister or strip packaging. This combination is a reliable revenue generator for third-party manufacturing partners seeking to expand their CNS product portfolio.